Clene (CLNN) Stock Price, News & Analysis

Company Overview

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.

Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders. CNM-Au8 remains an investigational therapy and is not approved for general commercial use.

Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities primarily through U.S.-based programs, while working with research and clinical collaborators as appropriate. The company is led by Chief Executive Officer Robert Etherington and trades on the Nasdaq under the symbol CLNN.

Key Stats

• Today's Range: $3.90 to $4.43
• 50-Day Range: $3.10 to $4.54
• 52-Week Range: $3.02 to $10.84
• Volume: 7,620 shs
• Average Volume: 209,402 shs
• Market Capitalization: $57.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $34.00
• Consensus Rating: Moderate Buy

Clene Stock Analysis - MarketRank™

Clene scored higher than 48% of companies evaluated by MarketBeat, and ranked 518th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Clene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Clene has a consensus price target of $34.00, representing about 750.0% upside from its current price of $4.00.

Amount of Analyst Coverage

Clene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Clene are expected to decrease in the coming year, from ($1.05) to ($1.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clene is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clene is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.04% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 5.06.

Change versus previous month

Short interest in Clene has recently decreased by 1.86%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clene does not currently pay a dividend.

Dividend Growth

Clene does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.48

News Sentiment

Clene has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Clene this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for CLNN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Clene insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

23.28% of the stock of Clene is held by institutions.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CLNN
• CIK: 1822791
• Web: clene.com
• Phone: 801-676-9695
• Fax: N/A
• Employees: 79
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Clene: $34.00
• High Price Target: $48.00
• Low Price Target: $23.00
• Potential Upside/Downside: +758.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.17 million
• Net Margins: -11,274.79%
• Pretax Margin: -11,271.43%
• Return on Equity: N/A
• Return on Assets: -77.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.85
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $200 thousand
• Price / Sales: 285.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.03) per share
• Price / Book: -3.84

Miscellaneous

• Outstanding Shares: 14,400,000
• Free Float: 10,325,000
• Market Cap: $57.02 million
• Optionable: Optionable
• Beta: 1.04